Therefore, due to its emerging role as a potential therapeutic target in multiple cancers, as well as the recent development of a small‐molecule MELK inhibitor (Chung et al, 2012), we selected this kinase for further study in order to determine its value as a potential therapeutic target in prostate cancer. This evidence concerns the gene MELK and prostate carcinoma.